Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Expected to Post Earnings of -$0.80 Per Share
Equities research analysts expect Collegium Pharmaceutical, Inc. (NASDAQ:COLL) to report earnings per share of ($0.80) for the current quarter, Zacks reports. Three analysts have made estimates for Collegium Pharmaceutical’s earnings. The highest EPS estimate is ($0.74) and the lowest is ($0.88). Collegium Pharmaceutical reported earnings of ($1.05) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 23.8%. The business is scheduled to report its next quarterly earnings results on Wednesday, August 9th.
According to Zacks, analysts expect that Collegium Pharmaceutical will report full-year earnings of ($3.10) per share for the current fiscal year, with EPS estimates ranging from ($3.39) to ($2.86). For the next year, analysts anticipate that the firm will post earnings of ($1.84) per share, with EPS estimates ranging from ($2.55) to ($1.31). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Collegium Pharmaceutical.
Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Wednesday, May 10th. The specialty pharmaceutical company reported ($0.79) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.98) by $0.19. The firm had revenue of $2.17 million during the quarter, compared to analysts’ expectations of $3.55 million.
A number of brokerages recently weighed in on COLL. Janney Montgomery Scott restated a “buy” rating and set a $25.00 target price on shares of Collegium Pharmaceutical in a report on Monday, June 12th. Zacks Investment Research downgraded shares of Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. Jefferies Group LLC set a $24.00 price target on shares of Collegium Pharmaceutical and gave the company a “buy” rating in a research report on Saturday, March 25th. Needham & Company LLC reduced their price target on shares of Collegium Pharmaceutical from $28.00 to $25.00 and set a “buy” rating for the company in a research report on Thursday, May 11th. Finally, ValuEngine upgraded shares of Collegium Pharmaceutical from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 22nd. Two research analysts have rated the stock with a sell rating and five have issued a buy rating to the company’s stock. Collegium Pharmaceutical has an average rating of “Hold” and a consensus price target of $22.83.
Shares of Collegium Pharmaceutical (NASDAQ COLL) traded down 0.41% during mid-day trading on Tuesday, reaching $12.23. The company’s stock had a trading volume of 293,271 shares. Collegium Pharmaceutical has a 12-month low of $7.37 and a 12-month high of $20.55. The company’s 50-day moving average price is $10.09 and its 200-day moving average price is $12.74. The stock’s market capitalization is $360.28 million.
In other news, insider Paul Brannelly purchased 10,000 shares of Collegium Pharmaceutical stock in a transaction that occurred on Friday, May 12th. The stock was acquired at an average price of $9.18 per share, for a total transaction of $91,800.00. Following the transaction, the insider now owns 110,227 shares in the company, valued at $1,011,883.86. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 25.76% of the stock is currently owned by corporate insiders.
Large investors have recently added to or reduced their stakes in the company. American International Group Inc. increased its stake in Collegium Pharmaceutical by 27.8% in the first quarter. American International Group Inc. now owns 9,948 shares of the specialty pharmaceutical company’s stock worth $100,000 after buying an additional 2,163 shares during the last quarter. Pier Capital LLC increased its stake in Collegium Pharmaceutical by 11.1% in the first quarter. Pier Capital LLC now owns 366,064 shares of the specialty pharmaceutical company’s stock worth $3,683,000 after buying an additional 36,435 shares during the last quarter. Trexquant Investment LP bought a new stake in Collegium Pharmaceutical during the first quarter worth about $259,000. Bank of New York Mellon Corp increased its stake in Collegium Pharmaceutical by 6.1% in the first quarter. Bank of New York Mellon Corp now owns 65,305 shares of the specialty pharmaceutical company’s stock worth $656,000 after buying an additional 3,775 shares during the last quarter. Finally, Tocqueville Asset Management L.P. increased its stake in Collegium Pharmaceutical by 38.5% in the first quarter. Tocqueville Asset Management L.P. now owns 108,000 shares of the specialty pharmaceutical company’s stock worth $1,086,000 after buying an additional 30,000 shares during the last quarter. Institutional investors own 82.30% of the company’s stock.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.